stockrow
Friday 6 November 2026
Export ORGO’s income statement to Excel — free account
Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
- Revenue
- −69.9%
- EPS
- −327.3%
- Free cash flow
- −2,048.8%
- Total debt
- +395.3%
Quarter to September 2026, against a year earlier
0.89
0.05
+5.95%
Follow ORGO
Alert me
Organogenesis (ORGO) P/E ratio
Organogenesis has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 140× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 57.6× | — |
| FY2024 | 0.0× | — |
| FY2023 | 114× | 445.15% |
| FY2022 | 21.0× | 67.89% |
| FY2021 | 12.5× | (75.13%) |
| FY2020 | 50.2× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 57.6× | — |
| 29 more quarters | Free account |
Against its own ten years
Low 0.0×
High 140×
Ten-year median
0.0×
Current reading's percentile
62
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| ORGO Organogenesis | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 148× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)